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ABSTRACT: Ketoprofen is a widely used nonsteroidal anti-
inﬂammatory drug (NSAID) that also exhibits cytotoxic
activity against various cancers. This makes ketoprofen an
attractive structural lead for the development of new NSAIDs
and cytotoxic agents. Recently, the incorporation of
carboranes as phenyl mimetics in structures of established
drugs has emerged as an attractive strategy in drug design.
Herein, we report the synthesis and evaluation of four novel carborane-containing derivatives of ketoprofen, two of which are
prodrug esters with an nitric oxide-releasing moiety. One of these prodrug esters exhibited high cytostatic activity against
melanoma and colon cancer cell lines. The most pronounced activity was found in cell lines that are sensitive to oxidative stress,
which was apparently induced by the ketoprofen analogue.
1. INTRODUCTION
Ketoprofen (Figure 1) is a nonsteroidal anti-inﬂammatory drug
(NSAID) belonging to the group of substituted propionic
acids. It is used to treat rheumatoid arthritis, osteoarthritis,
dysmenorrhea, and to alleviate moderate pain. Ketoprofen has
pharmacologic activity similar to that of other NSAIDs, and
this is associated with the inhibition of prostaglandin synthesis
catalyzed by both cyclooxygenase (COX) isoforms, COX-1
and COX-2. Its anti-inﬂammatory eﬀects result from the
inhibition of both COX-1 and COX-2, the latter being
responsible for the production of prostaglandins under
inﬂammatory conditions.1−3 In addition to its eﬀects on
COX, ketoprofen inhibits the lipoxygenase pathway of the
arachidonic acid cascade. It is known that lipoxygenase
inhibitors have also the potential to attenuate inﬂammation,
and this inhibition is complementary to the COX inhibitory
action.4,5 Furthermore, it is a powerful inhibitor of bradykinin,
an important peptidic mediator of pain and inﬂammation.2
Generally, the side eﬀects of ketoprofen are similar to those
of other classical NSAIDs.7 Serious side eﬀects result mostly
from gastrointestinal (GI) damage. In fact, ketoprofen is
known to be one of the most ulcerogenic NSAIDs with a risk
factor for serious GI complications close to that of ibuprofen.8
These side eﬀects are mainly caused by the fact that ketoprofen
is a nonselective COX inhibitor. In contrast to COX-2, COX-1
is constitutively expressed within the body and is responsible
for the production of prostaglandins that have important
physiological functions, and thus inhibition of this isoform can
result in side eﬀects.9
The search for therapeutics with fewer side eﬀects has led to
the development of nitric oxide (NO)-releasing prodrugs of
established drugs.10,11 Given the gastrotoxicity of ketoprofen,
the design of an NO-releasing prodrug is beneﬁcial as NO
exhibits cytoprotective properties in the digestive mucosa.12
There are known examples of NO-releasing analogues of
ketoprofen that have an aliphatic-linked NO-releasing moiety,
i.e., a nitrate. The antinociceptive eﬀect and eﬃcacy of these
compounds were tested on rats, and one of the compounds,
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Figure 1. Ketoprofen and the nitric oxide (NO)-releasing analogue of
ketoprofen HCT-2037.6
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HCT-2037 (Figure 1), was found to be a potent and eﬀective
analgesic agent.6
The versatile biological role of NSAIDs is further fortiﬁed by
the ﬁndings that besides their anti-inﬂammatory action they
exhibit cytotoxic properties.13−15 Ketoprofen was found to
exhibit cytostatic activity against various cancer types,
including cervical cancer,16 osteosarcoma,17 and colon
cancer,16,18 based on diverse eﬀects ranging from inhibition
of metastasis17 to aﬀecting angiogenesis.19
Due to their importance for the treatment of inﬂammation
and their cytotoxic potential, new NSAIDs are constantly
developed, mostly by derivatizing established COX inhibitors.
An attractive drug design strategy is the incorporation of
dicarba-closo-dodecaboranes, or carboranes,20,21 in place of
hydrophobic moieties.22,23 Carboranes are icosahedral clusters
composed of 2 CH and 10 BH vertices. Based on the
arrangement of the carbon atoms within the boron cluster,
ortho, meta, and para isomers exist. Due to their size, shape,
and hydrophobicity, they are considered as phenyl mimetics,23
and several examples of carboranyl analogues of NSAIDs have
been studied already.24−28 In the case of indomethacin,
substitution of one phenyl ring with a carborane cluster
resulted in a shift from nonselective to COX-2-selective
inhibitory activity.24 Furthermore, due to their high boron
content, boron clusters are used in boron neutron capture
therapy.20,21,29,30 Incorporation of a carborane moiety in the
scaﬀolds of bioactive molecules is expected to increase their
metabolic stability given that carborane clusters are highly
resilient toward metabolic transformations.23,31
Herein, we report the synthesis of carborane-containing
derivatives of ketoprofen. The carborane moiety was intended
to induce selectivity toward COX-2 and increase the metabolic
stability of the resulting ketoprofen analogue. Furthermore, we
introduced NO-releasing moieties to obtain derivatives that
incorporate the beneﬁcial cytoprotective activity of NO.32 The
synthesized compounds were tested to determine their
potential as COX inhibitors as well as for their potential
cytotoxic activity.
2. RESULTS AND DISCUSSION
2.1. Molecular Design and Synthesis of Ketoprofen
Analogues. Ketoprofen’s molecular structure features two
phenyl rings, which, in principle, allow for introduction of the
carborane moiety. In this work, the nonsubstituted ring was
chosen to be replaced with a carborane cluster (Scheme 1,
compounds 3 and 4) as metabolic transformations of
ketoprofen occur at this phenyl ring.33 This is also a good
surrogate for comparing the eﬀect of a carborane substitution
of a keto-bound benzene ring to the biological activity of the
native drug.
As the most viable option for the synthesis of the carboranyl
derivative of ketoprofen, the synthetic methodology involving a
reaction between a lithio carborane and an acyl halide was
chosen. This synthetic approach was performed with both an
ortho-carborane and a meta-carborane to examine the eﬀect of
the position of the cluster carbon atoms on the chemical and
biological properties of the compound. The meta isomer may
be preferred as it is more stable toward deboronation
compared to its ortho counterpart.23 On the other hand, the
ortho cluster can be easily transformed into a nido-carborane,34
which may also be beneﬁcial for the properties of the
ketoprofen analogue.
The reaction conditions were chosen based on those
previously reported by Zakharkin et al. for the synthesis of a
methyl ketone derivative of ortho-carborane.35 To obtain a
high yield of the monosubstituted derivative, a mixture of
toluene and diethyl ether was used as the solvent for the
lithiation step, and an equimolar amount of n-BuLi was reacted
with ortho- or meta-carborane. The lithiated carborane was
then added to freshly prepared 3-(1-cyanoethyl)benzoyl
chloride dissolved in diethyl ether (Scheme 1). The addition
step should be performed by adding the nucleophile to the
electrophile to minimize the possibility of reduction of the
newly formed keto group to a tertiary alcohol. By this
approach, compounds 1 and 2 were obtained. Besides the
characterization of the intermediates, the molecular structure
of the ortho derivative 1 could be veriﬁed by X-ray
Scheme 1. Synthesis of Ketoprofen Analogues 3 (from ortho-Carborane) and 4 (from meta-Carborane)a
a(i) SOCl2, reﬂux; (ii) n-BuLi, anhydrous Et2O, and toluene (1:1) at −40 °C; (iii) with either 1 (for 3) or 2 (for 4) as starting material; mixture of
acetic acid and 6 M HCl (2:1), reﬂuxed overnight.
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crystallography (Supporting Information (SI), Table S1, Figure
S1).
The synthesis of the propionitrile derivatives 1 and 2 created
intermediates that could be further transformed into the
desired propionic acid derivatives 3 and 4 (Scheme 1). This is
easily achievable by hydrolysis of the cyano group to a
carboxylic group under acidic or basic conditions. To minimize
the possibility of a deboronation side reaction of ortho-
carborane, which is even more likely to occur due to the
electron-withdrawing carbonyl group attached at the carborane
cluster,36 the nitrile hydrolysis was done under acidic
conditions. The hydrolysis was performed under reﬂux
employing a mixture of acetic acid as the solvent and
concentrated hydrochloric acid. This aﬀorded the ketoprofen
analogues 3 and 4 in quantitative yields. 3 and 4 were fully
characterized and their structures were conﬁrmed by X-ray
crystallography (Figure 2; SI, Tables S2, S3 and Figures S2,
S3).
To expand the functionality of the synthesized carboranyl
derivatives of ketoprofen, a nitrate group was introduced to
generate a prodrug with an NO-releasing moiety. Within the
carborane-based ketoprofen analogues, the carboxylic group is
the most accessible functionality to insert a linker with one or
more nitrate groups attached. For this work, an aliphatic
derivative of dinitroglycerol was chosen because aromatic
linkers are known to be associated with increased carcinoge-
nicity.37 Furthermore, this allows the release of two NO
molecules per inhibitor molecule. Activation of the carboxylic
group as acyl halide and reaction with 1,3-dinitroglycerol or
the corresponding alcoholate did not yield the desired product,
even after prolonged reaction times and at elevated temper-
ature. This may be attributed to the poor nucleophilicity of
1,3-dinitroglycerol. Finally, the dinitrate esters 5 and 6 could
successfully be generated by employing Steglich esteriﬁcation
conditions with dicyclohexylcarbodiimide (DCC) and 4-
dimethylaminopyridine (DMAP) as coupling reagents
(Scheme 2). Due to the presence of a chiral center in the
nitrate esters 5 and 6, the methylene protons of the isopropyl
group are diastereotopic and can be observed as pairs of
doublets via coupling to the methine proton in the 1H NMR
spectra.
2.2. Evaluation of COX Inhibitory and Cytotoxic
Activities. All compounds were tested for their COX
inhibitory activity employing a commercial enzymatic COX
assay (“COX Fluorescent Inhibitor Screening Assay Kit”, Item
no. 700100, Cayman Chemical, Ann Arbor, MI) as described
elsewhere.38 However, only compound 5, the ketoprofen
analogue bearing an ortho-carborane and a nitrate moiety,
exhibited weak COX inhibition without selectivity for one of
the isoforms (SI, Table S4). The other compounds did not
exhibit any COX inhibitory activity.
To investigate the antitumor activity of the carboranyl
analogues of ketoprofen, three melanoma as well as three colon
cancer cell lines were used. The selection of the cell lines was
based on their ability to express COX-2; A375,39 B16F10,40
B16,41 CT26CL2542 are expressing COX-2, whereas HCT116
and SW480 do not.43 The four synthesized compounds were
applied at 0.8−50 μM, and the percentage of viable cells was
determined by measuring mitochondrial respiration [MTT
assay employing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide] as well as DNA/RNA content of attached
cells (crystal violet (CV) assay employing crystal violet). After
48 h incubation, the colorimetric assays revealed that only
compound 6 aﬀected cell viability of the tested cells in a dose-
dependent manner with an inhibitory activity varying among
the cell lines (Table 1).
Interestingly, the highest sensitivity was found for the COX-
2-expressing melanoma cell line A375 and the COX-2-negative
colon cancer cell line HCT116, indicating that the cytotoxic
activity of 6 is probably COX-2 independent. This is consistent
with the observation that 6 does not exhibit COX inhibitory
activity. Comparing the sensitivities among the diﬀerent cell
lines showed that the redox-sensitive cell lines44 are most
susceptible to 6. The IC50 values determined with both assays
Figure 2. Crystal structures of the ortho-carboranyl derivative of
ketoprofen 3 (left) and the meta-carboranyl derivative 4 (right). (Oak
Ridge thermal ellipsoid plot: displacement thermal ellipsoids are
drawn at 50% probability level. Hydrogen atoms are omitted for
clarity.) Detailed crystallographic parameters can be found in the SI
(Tables S2 and S3).
Scheme 2. Steglich Esteriﬁcation To Generate the NO-Releasing Prodrugs 5 and 6a
a(i) With either 3 (for 5) or 4 (for 6) as starting material; DCC, DMAP, CH2Cl2.
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(MTT, CV) were similar and showed that 6 aﬀects the cell
viability in a micromolar range; in contrast, ketoprofen did not
aﬀect cell viability in the same dose range (Figure 3). This
result is in agreement with the previously reported low
eﬀectiveness of ketoprofen against diﬀerent cell lines.45−47
However, a signiﬁcant cytostatic eﬀect was observed upon
exposure of human cervical carcinoma (HeLa) and human
colon cancer cells (Caco-2) to ketoprofen, which may be
attributed to the NF-κB inhibition that was detected.16
Comparison of sensitivities toward 6 of malignant cells
(Table 1) versus primary macrophages (IC50 = 46.55 ± 3.36
μM) showed that the compound is relatively selective for
cancer cells; a selectivity index toward the transformed
phenotype is given in Table S5, SI. Given that 6 showed
high activity against the A375 melanoma cells, this cell line was
used to determine the mechanism of the cytotoxic eﬀect of
ketoprofen analogue 6. To determine the main cause of
decreased cell viability, the inﬂuence of 6 on cell division and
cell death was investigated. As presented in Figure 4A, cell
division was inhibited upon 48 h treatment of A375 cells with
6. Within the same period, only 5% of double-positive, late-
apoptotic cells were determined suggesting only a symbolic
contribution of that type of cell death to decreased viability in
response to compound 6 (Figure 4B). Accordingly, only a
small ampliﬁcation of total caspase activity was observed after
the treatment (Figure 4C). Given that minor apoptosis usually
correlates with autophagic processes, the cells were examined
for the presence of autophagosomes. Indeed, enhanced
autophagy was detected by ﬂow cytometry after acridine
orange (AO) staining in response to the treatment with 6
(Figure 4D). In fact, it is well documented that apoptosis and
autophagy confront each other, but under some circumstances,
autophagy becomes a regular way of cell death, so it can
contribute to the cytotoxicity of compound 6.44
Table 1. Cytotoxic Activities of Compounds 3−6a
compounds 3 4 5 6
IC50 (μM) assay MTT CV MTT CV MTT CV MTT CV
cell lineb A375 >50 >50 >50 >50 >50 >50 17.15 ± 1.55 19.7 ± 0.0c
B16 >50 >50 >50 >50 >50 >50 23.1 ± 0.0c 24.5 ± 0.0c
B16F10 >50 >50 >50 >50 >50 >50 47.25 ± 2.75 46.15 ± 3.86
HCT116 >50 >50 >50 >50 >50 >50 11 ± 1.2 18.95 ± 0.95
CT26CL25 >50 >50 >50 >50 >50 >50 32.55 ± 3.17 50 ± 0.0c
SW480 >50 >50 >50 >50 >50 >50 50 ± 0.0c 49.4 ± 0.6
aIC50 values determined by MTT and CV assays (three independent experiments each).
bA375: human melanoma, B16: mouse solid melanoma,
B16F10: mouse metastatic melanoma, HCT116: human colon carcinoma, CT25CL26: mouse colon carcinoma, SW480: human colon carcinoma.
cStandard deviation varies in the third decimal place.
Figure 3. Eﬀect of ketoprofen and 6 on the cell viability of diﬀerent cell lines. Cells were exposed to 6 (A) or ketoprofen (B) for 48 h, and cell
viability was analyzed using MTT (left panel) and CV assays (right panel). *p < 0.05 compared to untreated controls.
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It has been reported that ketoprofen induced oxidative
damage of gastrointestinal mucosa,48 and it was attempted to
circumvent this damage by incorporating an NO-releasing
moiety based on the cytoprotective, prostaglandin-like proper-
ties of NO.6 Since 6 is designed to be an NO-releasing
ketoprofen analogue, the level of intracellular as well as
extracellular NO in response to the treatment was determined.
The release of NO from a nitrate moiety is a three-electron
reduction that is normally catalyzed by multiple possible
enzymes.49 However, compound 6 was found not to aﬀect the
intracellular amount of NO in A375 cells (Figure 5A). Having
in mind that A375 cells are able to produce NO, it can be
concluded that compound 6 neither liberated NO nor changed
endogenous production of this molecule in the melanoma cell
line. Given that NO donors also release NO extracellularly and
that the absence of intracellular NO release is not a proof that
a compound is not able to liberate NO at all, spontaneous as
well as the extracellular release of NO from 6 was measured.
Release of NO in the extracellular compartment is typically
determined by the Griess reaction that measures the resultant
nitrite accumulation.50,51 Nitrite accumulation was measured
in culture medium, conditioned culture medium (medium
taken from cell cultures upon incubation for 72 h) that
contains soluble cellular products or cell debris, as well as in
the supernatants from A375 cells that were exposed to 6 (10−
40 μM) for 48 h. However, the determined nitrite
accumulation was at the detection limit of the Griess reaction
(1.5 μM), even at the highest applied dose, suggesting that 6
did not release NO in the extracellular compartment.
Moreover, the production of reactive oxygen species/reactive
nitrogen species (ROS/RNS) was measured employing
dihydrorhodamine-123 (DHR). Indeed, ROS/RNS produc-
tion was elevated after the exposure to 6 (Figure 5B),
indicating that the compound promoted oxidative stress, which
Figure 4. Mechanism of the cytotoxic action of 6 against A375 cells. Cells were exposed to 6 for 48 h, and cell proliferation (A), presence of
apoptosis by Ann/propidium iodide (PI) (Annexin V-ﬂuorescein isothiocyanate (FITC)/propidium iodide) double staining (B), caspase activation
by apostat (C), and autophagy by AO staining (D) were assessed by ﬂow cytometry. Treatments with 6 are presented as black-lined histograms and
controls as gray histograms.
Figure 5. Mechanism of cytotoxic action of 6 against A375 cells. Intracellular NO (A) and ROS/RNS production (B) were measured after
incubation with 6 for 48 h by ﬂow cytometry. Treatments with 6 are presented as black-lined histograms and controls as gray histograms.
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correlates with the fact that cell lines highly susceptible to
oxidative stress were aﬀected most by 6.
3. CONCLUSIONS
We report the synthesis of two carboranyl analogues of
ketoprofen bearing an ortho- or meta-carborane (3 and 4), as
well as derivatives additionally bearing nitrate moieties (5 and
6). The ortho-carborane nitrate ester 5 showed weak COX
inhibitory activity. On the other hand, compound 6, the meta-
carborane analogue of 5, exhibited cytotoxic activity toward
colon and melanoma cancer cell lines in the micromolar range
with a special eﬀect on the A375 cell line. It was determined
that the cytotoxic eﬀect is due to its potential to promote
autophagy and oxidative stress in cells. Further research should
provide better insights into the mechanism of action and the
molecular targets of the ketoprofen analogue 6.
4. EXPERIMENTAL SECTION
4.1. Syntheses. 4.1.1. Materials and Methods. All
commercial reagents and solvents were used without further
puriﬁcation. Reactions including carboranes were carried out
under a nitrogen atmosphere using the standard Schlenk
technique. Compounds 2, 4, and 6 were synthesized with 10B-
enriched m-carborane. For column chromatography, silica gel
(60 Å) from the company ACROS was used. The particle size
was in the range of 0.035−0.070 mm. Thin-layer chromatog-
raphy was used to monitor the reaction process of the
syntheses. For this purpose, glass plates coated with silica gel
plates 60 F254 from the company MERCK were used.
Carborane-containing substances were stained with a 5%
solution of palladium chloride in methanol (MeOH). All
received 1H, 13C, and 11B NMR spectra were recorded with an
ADVANCE DRX 400 spectrometer from BRUKER. The
chemical shifts are reported in parts per million (ppm).
Quaternary carbons (e.g. substituted cluster carbon atoms)
were not always observed because of their long relaxation time.
The melting points were determined in glass capillaries using a
GALLENKAMP apparatus and were uncorrected. IR spectra
were obtained using an FTIR spectrometer (GENESIS ATI,
Mattson/Unicam) in the range of 400−4000 cm−1 in KBr.
High-resolution mass spectra in the positive or negative mode
were recorded with a BRUKER Daltonics APEX II FT-ICR
spectrometer. For these measurements, dichloromethane,
acetonitrile (ACN), methanol (MeOH), formic acid (FA), or
a mixture of these solvents was used.
Compounds 1−6 were obtained and employed as racemic
mixtures.
4 .1 .2 . Synthes i s o f 2- [3 - (1 ,2 -D icarba-c loso-
dodecaboranoyl)phenyl]propionitrile (1). o-Carborane
(0.0144 mol, 1.64 g) was dissolved in a mixture of dry Et2O
and toluene (1:1). To this solution, 7.6 mL of n-BuLi (1 equiv)
was added dropwise at −40 °C. The reaction mixture was
stirred at −40 °C for 1 h. Separately, 3-(1-cyanoethyl)benzoyl
chloride was prepared by reﬂuxing 2 g (0.0144 mol) of 3-(1-
cyanoethyl)benzoic acid in SOCl2 (10 mL) for 1 h. Excess
SOCl2 was removed under reduced pressure, and the acid
halide was dissolved in 10 mL of dry diethyl ether. The
solution of lithiated m-carborane was then added dropwise at
−40 °C to the solution of 3-(1-cyanoethyl)benzoyl chloride,
and the reaction was left to slowly warm to room temperature
overnight. The reaction mixture was washed with 2 M HCl.
The organic phase was collected, dried over MgSO4, and the
solvent was removed under reduced pressure to yield a yellow
viscous oil. Puriﬁcation was carried out by column
chromatography (n-hexane/ethyl acetate 4:1). This gave
compound 1 as a colorless solid. Yield: 32% (1.4 g, 4.6
mmol); mp: 69−70 °C. 1H NMR (CDCl3, 400 MHz): δ =
8.04 (d, 1H, CHaromat), 7.97 (s, 1H, CHaromat), 7.7 (d, 1H,
CHaromat), 7.56 (t, 1H, CHaromat), 4.56 (s, 1H, CHcluster), 4.00
(q, 3JHH = 8 Hz, 1H, CH), 1.71 (d,
3JHH = 8 Hz, 3H, CH3),
3.2−1.7 (m, 10H, BHcluster); 11B{1H} NMR (CDCl3, 128
MHz): δ = −1.3 (s, 1B), −2.7 (s, 2B), −8.0 (s, 3B), −11.7 (s,
2B), −13.4 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): δ =
219.7 (CO), 185.2 (CN), 137.9 (qCaromat), 134.0 (qCaromat),
132.5 (CHaromat), 130.1 (CHaromat), 129.5 (CHaromat), 128.6
(CHaromat), 59.2 (CHcluster), 32.1 (CH), 21.2 (CH3); IR (KBr,
cm−1): ṽ = 3044 (m, ν(C−Hcluster)), 2992−2877 (w, ν(C−
Haliphat)), 2615 (s, ν(B−H)), 2240 (w, ν(CN)) 1687 (s,
ν(CO)); high-resolution electrospray ionization mass
spectrometry (HR-ESI-MS) (negative mode, ACN) m/z [M
− H]−: calcd for C12H18B10NO: 300.2391, found: 300.2401;
the observed isotopic pattern was in agreement with the
calculated one. Elemental analysis: calcd for C: 47.82, H: 6.47,
N: 4.65, found for C: 47.79, H: 6.35, N: 4.49.
4 .1 .3 . Synthes i s o f 2 - [3 - (1 ,7 -D icarba-c loso-
dodecaboranoyl)phenyl]propionitrile (2). This compound
was synthesized in a manner similar as described for the
ortho isomer, starting from 1.5 g (0.011 mol) of m-carborane.
Compound 2 was obtained as a colorless solid. Yield: 32% (1.1
g, 3.65 mmol); mp: 80−81 °C. 1H NMR (CDCl3, 400 MHz):
δ = 7.64−7.54 (m, 3H, CHaromat), 7.46 (t, 1H, CHaromat), 3.95
(q, 3JHH = 8 Hz, 1H, CH), 3.09 (s, 1H, CHcluster), 1.67 (d,
3JHH
= 8 Hz, 3H, CH3), 3.35−1.4 (m, 10H, BHcluster); 11B{1H}
NMR (CDCl3, 128 MHz): δ = −5.5 (br, 3B), −10.8 (br, 3B),
−12.9 (s, 2B), −15.2 (s, 2B); 13C{1H} NMR (CDCl3, 100
MHz): δ = 188.4 (CO), 137.4 (qCaromat), 137.1 (qCaromat),
130.6 (CHaromat), 129.0 (CHaromat), 128.3 (CHaromat), 126.9
(CHaromat), 120.8 (CN), 55.0 (CHcluster), 31.0 (CH), 21.2
(CH3); IR (KBr, cm
−1): ṽ = 3072 (m, ν(C−Hcluster)), 2998−
2870 (w, ν(C−Haliphat)), 2615 (s, ν(B−H)), 2247 (s, ν(C
N)), 1683 (s, ν(CO)); HR-ESI-MS (positive, ACN) m/z
[M + Na]+: calcd for C12H19
10B10NNaO: 316.2658, found:
316.2672; the observed isotopic pattern was in agreement with
the calculated one. Elemental analysis: calcd for C: 49.12, H:
6.52, N: 4.77, found for C: 48.26, H: 6.47, N: 4.77.
4 .1 .4 . Synthes i s o f 2 - [3 - (1 ,2 -D icarba-c loso-
dodecaboranoyl)phenyl]propanoic Acid (3). Compound 1
(1 g, 3.32 mmol) was dissolved in 20 mL of acetic acid and 10
mL of 6 M HCl. The solution was left to reﬂux overnight and
then it was neutralized with saturated NaHCO3. The resulting
slurry was extracted with ethyl acetate (2 × 30 mL). The
organic phase was collected and dried over anhydrous MgSO4,
and the solvent was removed under reduced pressure.
Puriﬁcation was carried out by column chromatography (n-
hexane/ethyl acetate 2:1). Yield: 96% (1.02 g, 3.18 mmol);
mp: 91−92 °C. 1H NMR (CDCl3, 400 MHz): δ = 7.99 (s, 1H,
CHaromat), 7.96 (d, 1H, CHaromat), 7.62 (d, 1H, CHaromat), 7.46
(t, 1H, CHaromat), 4.55 (s, 1H, CHcluster), 3.83 (q,
3JHH = 7.1
Hz, 1H, CH), 1.57 (d, 3JHH = 7.1 Hz, 3H, CH3), 3.45−1.6 (m,
10H, BHcluster);
11B{1H} NMR (CDCl3, 128 MHz): δ = −1.4
(s, 1B), −2.5 (s, 2B), −8.1 (s, 2B), −11.5 (s, 3B), −13.4 (s,
2B); 13C{1H} NMR (CDCl3, 100 MHz): δ = 185.2 (CO),
178.4 (COOH), 140.4 (qCaromat), 133.7 (CHaromat), 133.4
(qCaromat), 129.7 (CHaromat), 128.9 (CHaromat), 59.2 (CHcluster),
44.9 (CH), 18.1 (CH3); IR (KBr, cm
−1): ṽ = 3088 (m, ν(C−
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Hcluster)), 3000−2726 (w, ν(C−Haliphat)), 2592 (s, ν(B−H)),
1713 (s, ν(CO)), 1671 (s, ν(CO)), 1263 (s, ν(C−O)),
1233 (s, ν(C−O)); HR-ESI-MS (negative mode, ACN) m/z
[M − CO2 − H]−: calcd for C11H19B10O 275.2439: found:
275.2483; m/z [M − H]−: calcd for C12H19B10O3: 319.2337,
found: 319.2370; the observed isotopic pattern was in
agreement with the calculated one. Elemental analysis: calcd
for C: 44.99, H: 6.29, found for C: 44.33, H: 6.22.
4 .1 .5 . Synthes i s o f 2- [3 - (1 ,7 -D icarba-c loso-
dodecaboranoyl)phenyl]propanoic Acid (4). This compound
was synthesized in a manner similar as described for the ortho
isomer starting from 0.95 g (3.15 mmol) of 2. Compound 4
was obtained as a colorless solid. Yield: 90% (0.91 g, 2.84
mmol); mp: 85−86 °C. 1H NMR (CDCl3, 400 MHz): δ =
7.61 (s, 1H, CHaromat), 7.56 (d, 1H, CHaromat), 7.50 (d, 1H,
CHaromat), 7.38 (t, CHaromat), 3.79 (q,
3JHH = 4 Hz, 1H, CH),
3.06 (s, 1H, CHcluster), 1.54 (d,
3JHH = 4 Hz, 3H, CH3), 3.36−
1.49 (m, 10H, BHcluster);
11B{1H} NMR (CDCl3, 128 MHz): δ
= −10.8 (br, 4B), −12.9 (s, 3B), −15.2 (s, 3B); 13C{1H} NMR
(CDCl3, ppm): δ = 188.5 (CO), 177.6 (COOH), 139.9
(qCaromat), 136.4 (qCaromat), 131.7 (CHaromat), 128.5
(CHaromat), 127.9 (CHaromat), 127.8 (CHaromat), 54.8
(CHcluster), 44.8 (CH), 18.2 (CH3); IR (KBr, cm
−1): ṽ =
2108−3000 (w, ν(C−Haromat)), 3000−2766 (w, ν(CHaliphat)),
2615 (s, ν(B−H)), 1717 (s, ν(CO)), 1687 (s, ν(CO)),
1279 (m, ν(C−O)), 1259 (m, ν(C−O)). HR-ESI-MS
(negative mode, ACN) m/z [M − CO2 − H]−: calcd for
C11H19
10B10O: 267.2730, found: 267.2792; m/z [M − H]−:
calcd for C12H19
10B10O3: 311.2628, found: 311.2672; the
observed isotopic pattern was in agreement with the calculated
one. Elemental analysis: calcd for C: 46.13, H: 6.45, found for
C: 45.40, H: 6.45.
4.1.6. Synthesis of 1,3-Bis(nitrooxy)propan-2-yl-2-[3-(1,2-
dicarba-closo-dodecaboranoyl)phenyl]propanoate (5). 2-
[3-(1,2-Dicarba-closo-dodecaboranoyl)phenyl]propanoic acid
(2.03 g, 8.0 mmol), 3.80 mL (40 mmol) of tert-butanol, 147
mg (1.2 mmol) of DMAP, and anhydrous CH2Cl2 (20 mL)
were added to a 100 mL round-bottom ﬂask. DCC (2.23 g,
10.8 mmol) was added in one portion to this stirred slurry.
The formation of a colorless precipitate was observed
immediately. After stirring at room temperature overnight,
the precipitate was removed via ﬁltration, and the ﬁltrate was
concentrated under vacuum. The residue was puriﬁed with
silica gel ﬂash chromatography using n-hexane/ethyl acetate
20:1 to 10:1 as an eluent. The desired product was obtained as
a viscous clear and colorless oil. Yield: 92% (2.28 g, 4.7 mmol).
1H NMR (CDCl3, 400 MHz): δ = 7.97 (d,
1H, CHaromat), 7.91
(s, 1H, CHaromatic), 7.55 (d, 1H, CHaromat), 7.46 (t, 1H,
CHaromat), 5.37 (m, 1H, CH), 4.74 (dd,
2JHH = 6 Hz,
4JHH =
12.8 Hz, 1H, CH), 4.64 (dd, 2JHH = 6 Hz,
4JHH = 12.8 Hz, 1H,
CH), 4.55 (dd, 2JHH = 6 Hz,
4JHH = 12.8 Hz, 2H, CH, and
CHcluster), 4.74 (dd,
2JHH = 6 Hz,
4JHH = 12.8 Hz, 1H, CH),
3.83 (q, 3JHH = 7.1 Hz, 1H, CH), 1.56 (d, 3H,
3JHH = 7.1 Hz,
CH3), 3.29−1.5 (m, 10H, BHcluster); 11B{1H} NMR (CDCl3,
128 MHz): δ = −1.4 (s, 1B), −2.8 (s, 2B), −8.1 (s, 2B), −11.5
(s, 3B), −13.5 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): δ =
184.9 (CO), 172.8 (COOR), 140.0 (qCaromat), 133.6
(qCaromat), 133.4 (CHaromat), 129.7 (CHaromat), 129.4
(CHaromat), 129.1 (CHaromat), 69.3 (CH2), 69.2 (CH2), 67.1
(CH), 59.2 (CHcluster), 45.0 (CH), 18.1 (CH3); IR (KBr,
cm−1): ṽ = 3094 (m, ν(C−Hcluster)), 2634−2556 (s, ν(B−
Hcluster)), 1741 (m, v(CO)), 1678 (s, ν(CO) or ν(NO)),
1636 (s, ν(CO) or ν(NO)), 1258 (s, ν(C−O) or ν(NO)),
851 (s, ν(N−O)). HR-ESI-MS (negative mode, ACN, FA) m/
z [M + FA − H]−: calculated for the formic acid (FA) adduct
C16H25B10N2O11: 529.2413, found: 529.2452; the observed
isotopic pattern was in agreement with the calculated one.
Elemental analysis: calcd for C: 37.19, H: 4.99, N: 5.78, found
for C: 37.37, H: 4.96, N: 5.80.
4.1.7. Synthesis of 1,3-Bis(nitrooxy)propan-2-yl-2-[3-(1,7-
dicarba-closo-dodecaboranoyl)phenyl]propanoate (6). This
compound was synthesized in a manner similar as described
for the ortho isomer starting from 0.7 g (2.22 mmol) of 4.
Compound 6 was obtained as a viscous clear and colorless oil.
Yield: 92% (0.99 g, 2.0 mmol). 1H NMR (CDCl3, 400 MHz):
δ = 7.57 (d, 1H, CHaromat), 7.54 (s, 1H, CHaromatic), 7.45 (d,
1H, CHaromat), 7.39 (t, 1H, CHaromat), 5.37 (m, 1H, CH), 4.75
(dd, 2JHH = 5.9 Hz,
4JHH = 12.7 Hz, 1H, CH), 4.63 (dd,
2JHH =
5.9 Hz, 4JHH = 12.7 Hz, 1H, CH), 4.55 (dd,
2JHH = 5.9 Hz,
4JHH = 12.7 Hz, 1H, CH), 4.47 (dd,
2JHH = 5.9 Hz,
4JHH = 12.7
Hz, 1H, CH), 3.79 (q, 3JHH = 7 Hz, 1H, CH), 3.08 (s, 1H,
CHcluster), 1.54 (d, 3H,
3JHH = 7 Hz, CH3), 3.29−1.45 (m,
10H, BHcluster);
11B{1H} NMR (CDCl3, 128 MHz): δ = −4.9
(s, 2B), −6.0 (s, 1B), −10.4 (s, 2B), −11.2 (s, 1B), −12.9 (s,
2B), −15.2 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): 188.4
(CO), 172.7 (COOR), 139.5 (qCaromat), 136.6 (qCaromat),
131.4 (CHaromat), 128.6 (CHaromat), 127.9 (CHaromat), 127.8
(CHaromat), 69.4 (CH2), 69.2 (CH2), 66.9 (CH), 55.1
(CHcluster), 45.0 (CH), 18.1 (CH3); IR (KBr, cm
−1): ṽ =
3067 (m, ν(C−Hcluster)), 2617 (s, ν(B−Hcluster)), 1746 (m,
v(CO)), 1647 (s, v(CO) or ν(N−O)), 1277 (s, ν(C−O)
or ν(NO)), 851 (s, ν(N−O)) HR-ESI-MS (negative mode,
ACN, FA) m/z [M + FA − H]−: calculated for the formic acid
(FA) adduct C16H25
10B10N2O11: 521.2752, found: 521.2695;
the observed isotopic pattern was in agreement with the
calculated one. Elemental analysis: calcd for C: 37.81, H: 5.07,
N: 5.87, found for C: 37.47, H: 5.06, N: 5.37.
4.2. Cell Viability Materials and Methods. 4.1.8. Re-
agents and Cells. Reagents were for the most part obtained
from Sigma (St. Louis, MO). Annexin V-FITC (AnnV) was
obtained from Biotium (Hayward, CA), and apostat was from
R&D (R&D Systems, Minneapolis, MN). The melanoma cell
lines A375, B16 and its metastatic subclone B16F10 as well as
the colon cancer cell lines HCT116, SW480, and CT26CL25
were cultivated in 10% fetal calf serum (FCS) Roswell Park
Memorial Institute (RPMI)-1640 medium with 2 mM L-
glutamine, 0.01% sodium pyruvate, and antibiotics at 37 °C in
a humidiﬁed atmosphere with 5% CO2. Upon trypsinization,
cells were seeded in a certain number: 2.5 × 103 cells/well for
96-well plates and viability assessment and 2 × 104 cells/well
for 24-well plates and ﬂow-cytometric analysis. C57BL/6 mice,
obtained from the animal facility at The Institute for Biological
Research “Sinisǎ Stankovic”́, were sacriﬁced for isolation of
peritoneal resident macrophages. For viability assessment, cells
were isolated by peritoneal lavage, washed, counted, seeded in
96-well plates and incubated overnight before drug application.
Before treatment, nonadherent cells were removed. Carborane-
based ketoprofen analogues were dissolved in dimethyl
sulfoxide (DMSO) and stored at −20 °C for a month. 10%
FCS−RPMI-1640 working solutions were prepared before the
experiment started. In each experiment, control cultures were
exposed to equal amounts of DMSO.
4.1.9. Cell Viability Tests. For viability assessment, two of
the most frequently used tests were employed: (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(MTT) and crystal violet (CV). Cells were exposed to 3−6
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in a wide range of doses for a certain time interval, and the
number of viable cells was determined as described.52
Nontreated cells were arbitrarily set to 100%, and according
to this, results were expressed as the percentage of control.
4.1.10. Annexin V-FITC/PI, Acridine Orange Staining, and
Caspase Detection. A375 cells were treated with 6 for 48 h
and, after trypsinization, stained with Annexin V-FITC (Ann)/
propidium iodide (PI) or apostat as proposed by the
manufacturer. To evaluate the presence of acidic vesicles,
markers of autophagy, in the cytoplasm of cells, after-treatment
staining with a 10 μM AO solution for 15 min at 37 °C was
done. At the end of incubation, cells were washed and ﬁnally
resuspended in phosphate buﬀer solution (PBS). At the end of
all staining procedures, cells were analyzed with CyFlow Space
Partec using the PartecFloMax software.
4.1.11. Cell Staining with Carboxyﬂuorescein Succinimid-
yl Ester (CFSE). For cell division rate determination, cells were
prestained with carboxyﬂuorescein diacetate succinimidyl ester
(CFSE) (1 μM) for 10 min at 37 °C. After dye removal, cells
were exposed to an IC50 dose of 6 and 48 h later analyzed by
CyFlow Space Partec using the PartecFloMax.
4.1.12. Measurement of Intracellular Nitric Oxide. 4-
Amino-5-methylamino-2′,7′-diﬂuoroﬂuorescein diacetate
(DAF-FM, 5 μM) was used for quantiﬁcation of the
intracellular level of NO. After an incubation time of 48 h,
the cells were incubated in phenol-red-free RPMI containing
DAF-FM for 1 h at 37 °C, washed, and additionally incubated
for 15 min in serum/phenol-red-free conditions to complete
de-esteriﬁcation of intracellular diacetate. Cells were resus-
pended in phosphate buﬀer solution (PBS) and analyzed as
described.
4.1.13. Measurement of Intracellular Reactive Oxygen
Species (ROS) and Reactive Nitrogen Species (RNS).
Dihydrorhodamine-123 (DHR) (1 μM) was used for detection
of ROS/RNS production. To determinate the inﬂuence of 6
on the redox status of A375 cells, they were stained with DHR
dye for 20 min prior to exposure to an IC50 dose of 6. After 48
h, cells were collected, washed, and resuspended in PBS and
analyzed with CyFlow Space Partec using PartecFloMax.
4.1.14. Nitrite Detection. For detection of NO release in the
culture supernatant, nitrite accumulation, as an indicator of
NO production, was measured after 48 h of cultivation in the
presence of 6 using the Griess method.53 For assessment of
spontaneous release of nitric oxide, 6 was diluted in the culture
medium or conditioned medium, collected from cell cultures
after three days of incubation. Certain aliquots of culture
supernatants were mixed with the same volume of the Griess
reagent prepared from 0.1% naphthylenediamine dihydro-
chloride and 1% sulfanilamide in 5% H3PO4, mixed in a 1:1
ratio. Plates were incubated for 10 min at room temperature,
and the absorbance was measured at 570 nm using a
microplate reader. The nitrite concentration was calculated
according to a standard curve derived from a range of NaNO2
concentrations.
4.1.15. Statistics. The results were obtained in triplicate.
IC50 concentrations were calculated from at least three
independent experiments. The signiﬁcance of the diﬀerences
between various treatments was calculated by the analysis of
variance, followed by the Student−Newman−Keuls test. A p
value of less than 0.05 was considered signiﬁcant in
comparison to untreated control cells.
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